Here’s the latest you can use right now on CSL share price declines.
- The most recent big move: CSL shares touched multi-year lows in April–May 2026, extending a roughly 50% decline over the previous 12 months as growth expectations and margins came under pressure. This included a slide to around A$122–125 intraday levels before closing near the low end in early May 2026.[3]
- Context from mid-2026 coverage: Analysts remain split on recovery timing, with targets often cited in the A$150–A$240 range depending on margin stabilization and the Seqirus demerger trajectory, while investors debated the pace of any rebound given the restructuring and capital allocation questions.[3]
- Earlier notable jolts: The stock has seen several sharp declines over 2025–2026 tied to guidance cuts, disappointing medium-term growth signals, and the Seqirus demerger timeline, with one of the worst single-day drops occurring when a major guidance reset was disclosed in August 2025.[3]
- Longer-term perspective: Media and broker commentary since late 2025 describe a difficult reset for CSL’s growth profile, with questions around ROIC trends and the pacing of the business reorganization contributing to a persistent valuation re-rating.[3]
If you’d like, I can pull the most up-to-date numbers and compile a short watchlist (current price, intraday high/low, latest broker notes) and create a quick chart showing CSL’s price trend over the last 12–18 months. I can also summarize what recent guidance and strategic moves (like the Seqirus demerger) imply for near-term price action. Please tell me which format you prefer (brief bullet summary, table, or chart).
Citations:
- CSL share price nearing multi-year lows around April–May 2026 with about a 50% 12-month decline.[3]
- Analyst ranges and optimism/pessimism about recovery timing in 2026.[3]
- Historical declines tied to guidance resets and Seqirus demerger expectations in 2025–2026.[3]
Sources
CSL shares (ASX: CSL) extended a brutal 12-month selloff, briefly touching A$122.48 before closing higher at A$124.41 on Tuesday, with the price touching it's lowest price levels since 2017 and capping a 50% decline that has stunned long-term holders of what was once Australia's most reliable healthcare compounder. In a potentially interesting twist, the latest
thebull.com.auCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comCSL, one of Australia's largest stocks by market value, plunged on resuming trade after two days on announcing a discounted $5 billion placement to fund the $11.7 billion acquisition of Swiss drugmaker Vifor Pharma.
economictimes.indiatimes.comThe ASX closed lower as CSL plunged after a profit downgrade, while rising Middle East tensions pressured investor sentiment.
azzet.comAll the latest CSL (ASX:CSL) share price movements, news, expert commentary and investing advice from The Motley Fool Australia.
www.fool.com.auCSL shares recover slightly after hitting an 8-year low as analysts highlight a potential upside from current levels.
www.fool.com.auCSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
investors.csl.comCSL shares (ASX:CSL) struck a fresh multi-year low at A$125.78, capping a 49.91% decline over twelve months as repeated guidance cuts and margin pressures continue to erode confidence in what was once Australia's most valuable healthcare stock. The CSL share price closed at their lowest level in nearly 10 years, extending a relentless stair-step decline
thebull.com.au